Marta López‐Yurda

Author

Marta López‐Yurda

Also Known As

Lopez-Yurda, Marta, M I Lopez, M Lopez, M. I. Lopez-Yurda, M. Lopez, M. Lopez-Yurda, M. Lopez‐Yurda, M. López, M.I. Lopez, Marta Cardoso Lopes

107

Publications

3.1K

Citations

H-Index

Concepts

All Affiliations

The Netherlands Cancer Institute Oncode Institute University of Amsterdam Leiden University Medical Center University Medical Center Utrecht

About

Marta López‐Yurda is an author at The Netherlands Cancer Institute specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	17	2.3K
2	Health Sciences	3	3	125
3	Public Health	2	2	65
4	Cell Biology	1	1	39
5	Cellular Therapies	1	1	65

Marta López‐Yurda

Publications

2.9K

Citations

H-Index

Page 1

	Year	Citations
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers Myriam Chalabi, Lorenzo F. Fanchi, Krijn K. Dijkstra, Nature Medicine Neoadjuvant ImmunotherapyTumor ImmunologyCancer ImmunosurveillanceGastrointestinal OncologyMedicine	2020	1.3K
First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group Marinde J. G. Bond, Karen Bolhuis, O. J. L. Loosveld, The Lancet Oncology Surgical OncologyHepatologyMedicineHepatobiliary TumorColorectal Cancer	2023	153
Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial S. Lot Aronson, Marta López‐Yurda, Simone N. Koole, The Lancet Oncology Cytoreductive SurgeryGynecologic SurgerySurgical OncologyGynecological SurgeryMedicine	2023	101
Relapse of Wilms' tumour and detection methods: a retrospective analysis of the 2001 Renal Tumour Study Group–International Society of Paediatric Oncology Wilms' tumour protocol database Jesper Brok, Marta López‐Yurda, Harm van Tinteren, The Lancet Oncology UrologyGenitourinary CancerPaediatric Oncology WilmsMedicineRenal Pathology	2018	100
Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study Marie José Kersten, Julia Driessen, Josée M. Zijlstra, Haematologica ImmunologyPathologyPrimary RefractoryImmunotherapyHematological Malignancy	2020	92
Reirradiation for Head-and-Neck Cancer: Delicate Balance Between Effectiveness and Toxicity Frank Hoebers, Wilma D. Heemsbergen, S. Moor, International Journal of Radiation OncologyBiologyPhysics Radiation TherapyHead-and-neck CancerMedicineHead And Neck CancerNeck Oncology	2011	91
A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study) Erica Brivio, Franco Locatelli, Marta López‐Yurda, Blood	2020	88
IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma Irene L. M. Reijers, Disha Rao, Judith M. Versluis, The Journal of Experimental Medicine Cancer ImmunosurveillanceMedicineDonimi TrialImmunologyTumor Immunity	2023	70
Individualised dosing of anti-thymocyte globulin in paediatric unrelated allogeneic haematopoietic stem-cell transplantation (PARACHUTE): a single-arm, phase 2 clinical trial Rick Admiraal, Stefan Nierkens, Marc Bierings, The Lancet Haematology Cell TherapyAnti-thymocyte GlobulinTransplantationMarrow TransplantationBone Marrow Failure	2022	65
Atezolizumab With or Without Radiotherapy for Advanced Squamous Cell Carcinoma of the Penis (The PERICLES Study): A Phase II Trial Hielke M. de Vries, Tynisha S. Rafael, Alberto Gil-Jimenez, Journal of Clinical Oncology	2023	61

Page 1